FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus
This article was originally published in RPM Report
Executive Summary
CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.